Secukinumab for hidradenitis suppurativa with heart risk
Part of Infections, Skin clinical trials.
This study looks at whether secukinumab (a drug used for hidradenitis suppurativa) affects heart health in people who also have high heart risk or heart plaque. You'd receive the standard care with secukinumab and undergo special heart imaging to see how the drug affects your arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have moderate to severe hidradenitis suppurativa (a skin condition with painful boils).
- You are already taking or planning to take secukinumab (an injected medicine for this condition).
- You need to qualify for a special heart scan, either because you have known heart plaque, a doctor says you need it, or you have high heart risk based on age and risk factors.
- You must not have had a heart attack, acute coronary event, or TIA (mini-stroke) in the last 6 months.
- You cannot be pregnant or breastfeeding, and must not have severe kidney disease, severe anemia, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with moderate to severe hidradenitis suppurativa (HS) who start treatment with secukinumab early. It aims to see how well the treatment works and how it affects the condition over time.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
This study looks at how well secukinumab (Cosentyx) works in real life for people with moderate-to-severe hidradenitis suppurativa (HS) in Canada. If you're just starting this treatment, researchers want to track your progress and side effects.
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests an injected drug called siplizumab for people with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with other treatments. The goal is to see if it safely reduces painful bumps and improves your skin condition.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.